Titanocene-Gold Heterometallic Complexes for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments using cisplatin and its derivatives face challenges such as acquired or intrinsic resistance, limited spectrum of activity, and high toxicity, necessitating the development of alternative metal complexes with improved efficacy and reduced side effects.
Innovation Solution
The development of titanocene-gold compounds, specifically heterometallic complexes with the general formula [(η-C5H5)2TiR4Au], which exhibit high activity against renal cancers, are more stable in physiological media, and demonstrate cytotoxicity against human cancer renal cell lines, inhibiting tumor growth and inducing apoptosis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cisplatin and its derivatives are used to treat cancer, then antitumor activity is achieved, but acquired or intrinsic resistance develops and toxicity increases
Solution Approach 1:
The patent combines titanium and gold metals in a heterometallic complex to create a composite material with enhanced antitumor activity. The heterometallic complex [(η-C5H5)2TiR4Au] integrates the properties of both metals, achieving synergistic effects that overcome cisplatin resistance while maintaining reduced toxicity compared to monometallic counterparts.
2Reliability
If titanocene dichloride is used to treat cancer, then considerable antitumor activity is exhibited in vitro and in vivo, but efficacy in Phase II clinical trials is too low
Solution Approach 1:
The patent modifies the chemical parameters of titanocene dichloride by replacing chloride ligands with thiolato ligands and incorporating a gold center. This parameter change in the molecular structure transforms the compound from having low clinical efficacy to exhibiting high antitumor activity with improved therapeutic index.
Solution Approach 2:
The heterometallic complex combines titanium and gold in a specific configuration, creating a composite material that overcomes the limitations of titanocene dichloride alone. The dual-metal structure provides enhanced stability and cytotoxicity, translating preclinical activity into potential clinical effectiveness.
3Reliability
If gold complexes are used to treat cancer, then cisplatin resistance is overcome, but DNA is not the primary target which limits mechanism-based optimization
Solution Approach 1:
The heterometallic complex integrates multiple functional capabilities within a single molecule. The titanium center provides one mode of action while the gold center provides another, enabling the compound to overcome resistance through multiple mechanisms simultaneously, enhancing adaptability in treating different cancer types and resistance patterns.
Data Source
AI summary
Titanocene-gold compounds are provided that are useful for treating cancers. The disclose compounds generally have a formula given by: